Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo <i>via</i> an adenosine‐dependent mechanism

Abstract excerpt

ABSTRACT As many as 10% of bone fractures heal poorly, and large bone defects resulting fromtrauma, tumor, or infection may not heal without surgical intervention. Activation of adenosine A 2A receptors (A 2A Rs) stimulates bone formation. Ticagrelor and dipyridamole inhibit platelet function by inhibiting P2Y 12 receptors and platelet phosphodiesterase, respectively, but share the capacity to inhibit...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiplatelet Therapy and Cardiovascular Diseases
• Share to Coronary Interventions and Diagnostics
• Share to Lipoproteins and Cardiovascular Health